CA2274414A1 - Proteine de poisson alimentaire a utiliser pour restaurer la fonction normale de l'insuline chez les personnes insulinoresistantes - Google Patents

Proteine de poisson alimentaire a utiliser pour restaurer la fonction normale de l'insuline chez les personnes insulinoresistantes Download PDF

Info

Publication number: CA2274414A1
Authority: CA; Canada
Prior art keywords: insulin; protein; rats; fed; glucose
Prior art date: 1999-06-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002274414A

Other languages

English (en)

Inventor

Helene Jacques

Charles Lavigne

Andre Marette

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Universite Laval

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-11

Filing date

1999-06-11

Publication date

2000-12-11

1999-06-11 Application filed by Universite Laval filed Critical Universite Laval

1999-06-11 Priority to CA002274414A priority Critical patent/CA2274414A1/fr

2000-06-12 Priority to EP00938413A priority patent/EP1185289A2/fr

2000-06-12 Priority to PCT/CA2000/000714 priority patent/WO2000077034A2/fr

2000-06-12 Priority to CA002376197A priority patent/CA2376197A1/fr

2000-06-12 Priority to AU53825/00A priority patent/AU5382500A/en

2000-12-11 Publication of CA2274414A1 publication Critical patent/CA2274414A1/fr

2004-08-30 Priority to US10/929,913 priority patent/US20050101523A1/en

Status Abandoned legal-status Critical Current

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical group N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims description 235
102000004877 Insulin Human genes 0.000 title claims description 117
108090001061 Insulin Proteins 0.000 title claims description 117
229940125396 insulin Drugs 0.000 title claims description 117
108010038218 Dietary Fish Proteins Proteins 0.000 title description 2
206010022489 Insulin Resistance Diseases 0.000 claims abstract description 37
208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 27
108010028690 Fish Proteins Proteins 0.000 claims abstract description 13
206010012601 diabetes mellitus Diseases 0.000 claims abstract description 9
235000020824 obesity Nutrition 0.000 claims abstract description 5
208000008589 Obesity Diseases 0.000 claims abstract description 4
241000124008 Mammalia Species 0.000 claims abstract 5
150000001413 amino acids Chemical class 0.000 claims description 38
108090000765 processed proteins & peptides Proteins 0.000 claims 2
229940079593 drug Drugs 0.000 claims 1
239000003814 drug Substances 0.000 claims 1
241000700159 Rattus Species 0.000 abstract description 162
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 abstract description 121
239000005018 casein Substances 0.000 abstract description 114
235000021240 caseins Nutrition 0.000 abstract description 114
108010073771 Soybean Proteins Proteins 0.000 abstract description 105
229940001941 soy protein Drugs 0.000 abstract description 105
235000018102 proteins Nutrition 0.000 abstract description 102
102000004169 proteins and genes Human genes 0.000 abstract description 102
108090000623 proteins and genes Proteins 0.000 abstract description 102
239000008103 glucose Substances 0.000 abstract description 91
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 90
230000000694 effects Effects 0.000 abstract description 24
210000003205 muscle Anatomy 0.000 abstract description 20
230000002093 peripheral effect Effects 0.000 abstract description 15
235000009200 high fat diet Nutrition 0.000 abstract description 12
239000005720 sucrose Substances 0.000 abstract description 12
229930006000 Sucrose Natural products 0.000 abstract description 6
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract description 6
238000010171 animal model Methods 0.000 abstract 1
102000011632 Caseins Human genes 0.000 description 117
108010076119 Caseins Proteins 0.000 description 117
235000005911 diet Nutrition 0.000 description 78
230000037213 diet Effects 0.000 description 60
235000012054 meals Nutrition 0.000 description 58
238000012360 testing method Methods 0.000 description 51
230000000291 postprandial effect Effects 0.000 description 44
241001465754 Metazoa Species 0.000 description 38
229940024606 amino acid Drugs 0.000 description 36
235000001014 amino acid Nutrition 0.000 description 36
239000003925 fat Substances 0.000 description 36
102000015781 Dietary Proteins Human genes 0.000 description 25
108010010256 Dietary Proteins Proteins 0.000 description 25
235000021245 dietary protein Nutrition 0.000 description 25
239000004475 Arginine Substances 0.000 description 24
102000051325 Glucagon Human genes 0.000 description 24
108060003199 Glucagon Proteins 0.000 description 24
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 24
235000009697 arginine Nutrition 0.000 description 24
229960003121 arginine Drugs 0.000 description 24
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 24
229960004666 glucagon Drugs 0.000 description 24
230000004044 response Effects 0.000 description 22
230000009471 action Effects 0.000 description 21
239000000203 mixture Substances 0.000 description 19
235000010469 Glycine max Nutrition 0.000 description 18
230000000378 dietary effect Effects 0.000 description 18
VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 17
108010075254 C-Peptide Proteins 0.000 description 17
210000004369 blood Anatomy 0.000 description 16
239000008280 blood Substances 0.000 description 16
210000001519 tissue Anatomy 0.000 description 16
VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 14
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 14
230000006362 insulin response pathway Effects 0.000 description 14
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 13
108091006300 SLC2A4 Proteins 0.000 description 13
238000001802 infusion Methods 0.000 description 13
102000058061 Glucose Transporter Type 4 Human genes 0.000 description 12
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 12
235000020776 essential amino acid Nutrition 0.000 description 12
239000003797 essential amino acid Substances 0.000 description 12
238000002474 experimental method Methods 0.000 description 12
230000037406 food intake Effects 0.000 description 11
229960003136 leucine Drugs 0.000 description 11
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 10
229960003767 alanine Drugs 0.000 description 10
PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 description 10
239000000835 fiber Substances 0.000 description 10
235000012631 food intake Nutrition 0.000 description 10
230000001965 increasing effect Effects 0.000 description 10
238000000034 method Methods 0.000 description 10
210000002027 skeletal muscle Anatomy 0.000 description 10
229960004295 valine Drugs 0.000 description 10
241000251468 Actinopterygii Species 0.000 description 9
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 9
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 9
235000019786 weight gain Nutrition 0.000 description 9
SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 8
239000004472 Lysine Substances 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 8
230000037396 body weight Effects 0.000 description 8
235000019516 cod Nutrition 0.000 description 8
230000004190 glucose uptake Effects 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
238000001990 intravenous administration Methods 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
239000004474 valine Substances 0.000 description 8
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
210000000577 adipose tissue Anatomy 0.000 description 7
150000005693 branched-chain amino acids Chemical class 0.000 description 7
238000011161 development Methods 0.000 description 7
230000008034 disappearance Effects 0.000 description 7
235000018977 lysine Nutrition 0.000 description 7
238000011282 treatment Methods 0.000 description 7
150000003626 triacylglycerols Chemical class 0.000 description 7
QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 6
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 6
210000003486 adipose tissue brown Anatomy 0.000 description 6
230000003247 decreasing effect Effects 0.000 description 6
230000003914 insulin secretion Effects 0.000 description 6
230000007246 mechanism Effects 0.000 description 6
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
230000004584 weight gain Effects 0.000 description 6
208000002705 Glucose Intolerance Diseases 0.000 description 5
206010018429 Glucose tolerance impaired Diseases 0.000 description 5
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 5
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
230000009286 beneficial effect Effects 0.000 description 5
210000004556 brain Anatomy 0.000 description 5
150000001720 carbohydrates Chemical class 0.000 description 5
235000014633 carbohydrates Nutrition 0.000 description 5
230000002596 correlated effect Effects 0.000 description 5
235000021323 fish oil Nutrition 0.000 description 5
235000013305 food Nutrition 0.000 description 5
230000006377 glucose transport Effects 0.000 description 5
229960002885 histidine Drugs 0.000 description 5
150000002632 lipids Chemical class 0.000 description 5
238000005259 measurement Methods 0.000 description 5
230000001404 mediated effect Effects 0.000 description 5
229960002429 proline Drugs 0.000 description 5
230000028327 secretion Effects 0.000 description 5
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 5
230000005945 translocation Effects 0.000 description 5
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 4
229930064664 L-arginine Natural products 0.000 description 4
235000014852 L-arginine Nutrition 0.000 description 4
241000700157 Rattus norvegicus Species 0.000 description 4
210000000593 adipose tissue white Anatomy 0.000 description 4
235000004279 alanine Nutrition 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
239000002285 corn oil Substances 0.000 description 4
235000005687 corn oil Nutrition 0.000 description 4
230000001610 euglycemic effect Effects 0.000 description 4
235000019197 fats Nutrition 0.000 description 4
230000004153 glucose metabolism Effects 0.000 description 4
238000007446 glucose tolerance test Methods 0.000 description 4
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
230000006872 improvement Effects 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
235000016709 nutrition Nutrition 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
229960004441 tyrosine Drugs 0.000 description 4
239000011782 vitamin Substances 0.000 description 4
235000013343 vitamin Nutrition 0.000 description 4
229940088594 vitamin Drugs 0.000 description 4
229930003231 vitamin Natural products 0.000 description 4
150000003722 vitamin derivatives Chemical class 0.000 description 4
102000017011 Glycated Hemoglobin A Human genes 0.000 description 3
108010014663 Glycated Hemoglobin A Proteins 0.000 description 3
239000004471 Glycine Substances 0.000 description 3
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 3
229960005261 aspartic acid Drugs 0.000 description 3
230000008901 benefit Effects 0.000 description 3
235000019577 caloric intake Nutrition 0.000 description 3
210000000170 cell membrane Anatomy 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
230000002354 daily effect Effects 0.000 description 3
235000020673 eicosapentaenoic acid Nutrition 0.000 description 3
JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 3
229960005135 eicosapentaenoic acid Drugs 0.000 description 3
210000003743 erythrocyte Anatomy 0.000 description 3
230000014509 gene expression Effects 0.000 description 3
230000002414 glycolytic effect Effects 0.000 description 3
208000006575 hypertriglyceridemia Diseases 0.000 description 3
229910052500 inorganic mineral Inorganic materials 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
239000011707 mineral Substances 0.000 description 3
235000020660 omega-3 fatty acid Nutrition 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
108010015776 Glucose oxidase Proteins 0.000 description 2
239000004366 Glucose oxidase Substances 0.000 description 2
241000282412 Homo Species 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
206010060378 Hyperinsulinaemia Diseases 0.000 description 2
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
239000004395 L-leucine Substances 0.000 description 2
235000019454 L-leucine Nutrition 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
229930182821 L-proline Natural products 0.000 description 2
108010013563 Lipoprotein Lipase Proteins 0.000 description 2
102000043296 Lipoprotein lipases Human genes 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
238000000540 analysis of variance Methods 0.000 description 2
230000001596 anti-secretagogue Effects 0.000 description 2
235000003704 aspartic acid Nutrition 0.000 description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
238000010241 blood sampling Methods 0.000 description 2
210000001715 carotid artery Anatomy 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
239000003240 coconut oil Substances 0.000 description 2
235000019864 coconut oil Nutrition 0.000 description 2
230000015961 delipidation Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
235000013367 dietary fats Nutrition 0.000 description 2
229960004132 diethyl ether Drugs 0.000 description 2
235000020669 docosahexaenoic acid Nutrition 0.000 description 2
230000004110 gluconeogenesis Effects 0.000 description 2
229940116332 glucose oxidase Drugs 0.000 description 2
235000019420 glucose oxidase Nutrition 0.000 description 2
230000002710 gonadal effect Effects 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
230000003451 hyperinsulinaemic effect Effects 0.000 description 2
201000008980 hyperinsulinism Diseases 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 2
238000004255 ion exchange chromatography Methods 0.000 description 2
229960002725 isoflurane Drugs 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
210000004731 jugular vein Anatomy 0.000 description 2
-1 leucine Chemical class 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
210000005228 liver tissue Anatomy 0.000 description 2
210000003141 lower extremity Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
238000010197 meta-analysis Methods 0.000 description 2
229960004452 methionine Drugs 0.000 description 2
210000000663 muscle cell Anatomy 0.000 description 2
230000001019 normoglycemic effect Effects 0.000 description 2
230000001590 oxidative effect Effects 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
230000000580 secretagogue effect Effects 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
238000010159 Duncan test Methods 0.000 description 1
208000032928 Dyslipidaemia Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
208000036391 Genetic obesity Diseases 0.000 description 1
102100022197 Glutamate receptor ionotropic, kainate 1 Human genes 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
101000900515 Homo sapiens Glutamate receptor ionotropic, kainate 1 Proteins 0.000 description 1
101000976075 Homo sapiens Insulin Proteins 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
235000019766 L-Lysine Nutrition 0.000 description 1
FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
229930195722 L-methionine Natural products 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
238000008214 LDL Cholesterol Methods 0.000 description 1
102000005455 Monosaccharide Transport Proteins Human genes 0.000 description 1
108010006769 Monosaccharide Transport Proteins Proteins 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
108010062497 VLDL Lipoproteins Proteins 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
230000023852 carbohydrate metabolic process Effects 0.000 description 1
235000021256 carbohydrate metabolism Nutrition 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229960001231 choline Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960004874 choline bitartrate Drugs 0.000 description 1
QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 1
230000004087 circulation Effects 0.000 description 1
229960002173 citrulline Drugs 0.000 description 1
239000000470 constituent Substances 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000001517 counterregulatory effect Effects 0.000 description 1
235000021316 daily nutritional intake Nutrition 0.000 description 1
230000009615 deamination Effects 0.000 description 1
238000006481 deamination reaction Methods 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000003544 deproteinization Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
235000015872 dietary supplement Nutrition 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229940090949 docosahexaenoic acid Drugs 0.000 description 1
KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
238000013111 euglycemic-hyperinsulinemic clamp technique Methods 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
235000019688 fish Nutrition 0.000 description 1
239000012530 fluid Substances 0.000 description 1
210000000245 forearm Anatomy 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000001890 gluconeogenic effect Effects 0.000 description 1
150000002303 glucose derivatives Chemical class 0.000 description 1
230000009229 glucose formation Effects 0.000 description 1
230000014101 glucose homeostasis Effects 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
230000002641 glycemic effect Effects 0.000 description 1
238000000227 grinding Methods 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940084769 humulin r Drugs 0.000 description 1
230000000910 hyperinsulinemic effect Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000037493 inherited obesity Diseases 0.000 description 1
210000001596 intra-abdominal fat Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
230000003050 macronutrient Effects 0.000 description 1
235000021073 macronutrients Nutrition 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000037353 metabolic pathway Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
235000020665 omega-6 fatty acid Nutrition 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000000171 quenching effect Effects 0.000 description 1
239000000700 radioactive tracer Substances 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000005070 sampling Methods 0.000 description 1
229940071440 soy protein isolate Drugs 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
239000008399 tap water Substances 0.000 description 1
229960003080 taurine Drugs 0.000 description 1
235000021195 test diet Nutrition 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/20—Animal feeding-stuffs from material of animal origin
- A23K10/22—Animal feeding-stuffs from material of animal origin from fish
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Polymers & Plastics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Food Science & Technology (AREA)
Immunology (AREA)
Zoology (AREA)
Mycology (AREA)
Nutrition Science (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Animal Husbandry (AREA)
Gastroenterology & Hepatology (AREA)
Botany (AREA)
Marine Sciences & Fisheries (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
Physiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pediatric Medicine (AREA)
Biotechnology (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)

CA002274414A 1999-06-11 1999-06-11 Proteine de poisson alimentaire a utiliser pour restaurer la fonction normale de l'insuline chez les personnes insulinoresistantes Abandoned CA2274414A1 (fr)

Priority Applications (6)

Application Number	Priority Date	Filing Date	Title
CA002274414A CA2274414A1 (fr)	1999-06-11	1999-06-11	Proteine de poisson alimentaire a utiliser pour restaurer la fonction normale de l'insuline chez les personnes insulinoresistantes
EP00938413A EP1185289A2 (fr)	1999-06-11	2000-06-12	Acides amines provenant de proteines de poisson et de soja ameliorant la sensibilite a l'insuline
PCT/CA2000/000714 WO2000077034A2 (fr)	1999-06-11	2000-06-12	Acides amines provenant de proteines de poisson et de soja ameliorant la sensibilite a l'insuline
CA002376197A CA2376197A1 (fr)	1999-06-11	2000-06-12	Acides amines provenant de proteines de poisson et de soja ameliorant la sensibilite a l'insuline
AU53825/00A AU5382500A (en)	1999-06-11	2000-06-12	Amino acids from fish and soy proteins improve insulin sensitivity
US10/929,913 US20050101523A1 (en)	1999-06-11	2004-08-30	Amino acids from fish and soy proteins improve insulin sensitivity

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA002274414A CA2274414A1 (fr)	1999-06-11	1999-06-11	Proteine de poisson alimentaire a utiliser pour restaurer la fonction normale de l'insuline chez les personnes insulinoresistantes

Publications (1)

Publication Number	Publication Date
CA2274414A1 true CA2274414A1 (fr)	2000-12-11

Family

ID=4163636

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002274414A Abandoned CA2274414A1 (fr)	1999-06-11	1999-06-11	Proteine de poisson alimentaire a utiliser pour restaurer la fonction normale de l'insuline chez les personnes insulinoresistantes

Country Status (5)

Country	Link
US (1)	US20050101523A1 (fr)
EP (1)	EP1185289A2 (fr)
AU (1)	AU5382500A (fr)
CA (1)	CA2274414A1 (fr)
WO (1)	WO2000077034A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ITMI20020147A1 (it)	2002-01-29	2003-07-29	Indena Spa	Estrazione purificazione e modificazione di polipeptidi da seme di soia
AU2003264256A1 (en) *	2002-09-04	2004-03-29	Dsm Ip Assets B.V.	A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
AU2002334520A1 (en)	2002-09-06	2004-03-29	Telefonaktiebolaget L M Ericsson (Publ)	Composite power amplifier
WO2004024177A1 (fr) *	2002-09-16	2004-03-25	Quest International Services B.V.	Methode de traitement ou de prevention de l'obesite et de troubles du metabolisme lipidique et compositions a utiliser conjointement avec celle-ci
NO320667B1 (no) *	2004-02-02	2006-01-16	Einar Lied	Andvendelse av en sammensetning basert på fiskekjøtt for fremstilling av et preparat som reduserer økningen i blodglukose etter fødeinntak
JP2008506771A (ja)	2004-07-19	2008-03-06	エヌ．ブイ．・ヌートリシア	血糖値を調節するためのアスパルテートを使用するための調製物
WO2007069716A1 (fr) *	2005-12-16	2007-06-21	Nippon Suisan Kaisha, Ltd.	Composition ayant un effet d'inhibition d'accumulation de graisses viscerales
US20080200422A1 (en) *	2007-01-09	2008-08-21	Cavener Douglas R	Methods for reduction of adipose tissue mass
AU2009328505B2 (en)	2008-12-19	2014-11-27	Panima Pharmaceuticals Ag	Human anti-alpha-synuclein autoantibodies
WO2012026575A1 (fr) *	2010-08-26	2012-03-01	日本水産株式会社	Développeur de la masse musculaire
WO2012074375A1 (fr)	2010-12-01	2012-06-07	N.V. Nutricia	Prévention ou traitement du surpoids et de l'obésité chez des patients atteints d'un diabète de type 2
HUE041391T2 (hu)	2011-06-23	2019-05-28	Biogen Int Neuroscience Gmbh	Anti-alfa-szinukleinkötõ molekulák
PL2948003T3 (pl)	2013-01-23	2021-01-25	Bottled Science Limited	Kompozycja napoju poprawiająca skórę
EP3048904A2 (fr)	2013-09-25	2016-08-03	Pronutria Biosciences, Inc.	Compositions et formulations pour le traitement des maladies de malabsorption et les affections inflammatoires des voies gastro-intestinales, leurs procédés de production et d'utilisation
CN103858820A (zh) *	2014-03-11	2014-06-18	广西大学	一种小型猪2型糖尿病模型的制备方法
JP6878115B2 (ja) *	2017-04-25	2021-05-26	オリエンタル酵母工業株式会社	低蛍光性実験動物用飼料およびその製造方法
CN114533768B (zh) *	2022-01-20	2023-07-07	中国疾病预防控制中心传染病预防控制所	乳酸杆菌益生菌CGMCC No.1.13855在制备糖尿病治疗药物中的应用
CN121086004A (zh) *	2025-08-20	2025-12-09	北京工商大学	保肝活性肽及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2395288A1 (fr) *	1977-06-23	1979-01-19	Ppn	Nouvelles compositions therapeutiques destinees notamment a la prevention et au traitement des maladies de plethore
JPS59161319A (ja) *	1983-03-04	1984-09-12	Nippon Bussan Kk	薬理作用を有する魚貝類エキスの製造方法
IL99699A (en) *	1990-10-10	2002-04-21	Autoimmune Inc	Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
JP3487079B2 (ja) *	1996-06-17	2004-01-13	不二製油株式会社	抗肥満食品
US5830434A (en) *	1997-02-26	1998-11-03	Medical University Of South Carolina Foundation For Research Development	Methods of treating non-insulin dependent diabetes mellitus with pancreatic polypeptide
US6143786A (en) *	1999-02-02	2000-11-07	Novartis Nutrition Ag	Oral arginine and insulin secretion
SE525797C2 (sv) *	1999-03-10	2005-04-26	Timberjan Ab	Medel och förfarande för bekämpning av sjukdomstillstånd i matsmältningsapparaten, förfarande för framställning av och användning av ett preparat som ett sådant medel, samt djufoder och förfarande för framställning av ett djurfoder
JP4053686B2 (ja) *	1999-04-28	2008-02-27	仙味エキス株式会社	生理活性健康食品

1999
- 1999-06-11 CA CA002274414A patent/CA2274414A1/fr not_active Abandoned
2000
- 2000-06-12 WO PCT/CA2000/000714 patent/WO2000077034A2/fr not_active Ceased
- 2000-06-12 AU AU53825/00A patent/AU5382500A/en not_active Abandoned
- 2000-06-12 EP EP00938413A patent/EP1185289A2/fr not_active Ceased
2004
- 2004-08-30 US US10/929,913 patent/US20050101523A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU5382500A (en)	2001-01-02
WO2000077034A2 (fr)	2000-12-21
US20050101523A1 (en)	2005-05-12
WO2000077034A3 (fr)	2001-07-12
EP1185289A2 (fr)	2002-03-13

Legal Events

Date	Code	Title	Description
2001-09-13	FZDE	Discontinued

Publication	Publication Date	Title
CA2274414A1 (fr)	2000-12-11	Proteine de poisson alimentaire a utiliser pour restaurer la fonction normale de l'insuline chez les personnes insulinoresistantes
Lavigne et al.	2001	Prevention of skeletal muscle insulin resistance by dietary cod protein in high fat-fed rats
Calbet et al.	2002	Plasma glucagon and insulin responses depend on the rate of appearance of amino acids after ingestion of different protein solutions in humans
Mansour et al.	2013	Nutrients related to GLP1 secretory responses
Lavigne et al.	2000	Cod and soy proteins compared with casein improve glucose tolerance and insulin sensitivity in rats
Van Loon et al.	2000	Ingestion of protein hydrolysate and amino acid–carbohydrate mixtures increases postexercise plasma insulin responses in men
Gaullier et al.	2005	Supplementation with conjugated linoleic acid for 24 months is well tolerated by and reduces body fat mass in healthy, overweight humans
Park et al.	2008	Effects of dietary Korean proso-millet protein on plasma adiponectin, HDL cholesterol, insulin levels, and gene expression in obese type 2 diabetic mice
Donato Jr et al.	2006	Effects of leucine supplementation on the body composition and protein status of rats submitted to food restriction
US9961932B2 (en)	2018-05-08	Muscle preservation in overweight or obese adult during weight loss program
Baum et al.	2006	A reduced carbohydrate, increased protein diet stabilizes glycemic control and minimizes adipose tissue glucose disposal in rats
Hettiarachchi et al.	1996	Growth Hormone–Induced Insulin Resistance and Its Relationship to Lipid Availability in the Rat
Medić et al.	2006	Effects of soybean D-LeciVita product on serum lipids and fatty acid composition in type 2 diabetic patients with hyperlipidemia
Mooradian et al.	2000	Monosaccharide-enriched diets cause hyperleptinemia without hypophagia
Verbrugghe et al.	2010	The glucose and insulin response to isoenergetic reduction of dietary energy sources in a true carnivore: the domestic cat (Felis catus)
Parr	1999	Insulin exposure and unifying aging
Donato Jr et al.	2007	Effects of leucine and phenylalanine supplementation during intermittent periods of food restriction and refeeding in adult rats
Boudry et al.	2023	Development of a functional dairy snack containing oleoylethanolamide that reduces food intake in normal-weight and obese minipigs
Koopmans et al.	2011	The existence of an insulin-stimulated glucose and non-essential but not essential amino acid substrate interaction in diabetic pigs
EP3773013B1 (fr)	2025-04-30	Régulation de l'insuline chez l'adulte en surpoids ou obèse durant une intervention à vie
Obeid et al.	2006	Postprandial glycogen and lipid synthesis in prednisolone-treated rats maintained on high-protein diets with varied carbohydrate levels
Paulussen	2022	The food matrix and its effect on human protein metabolism
Shi et al.	2011	Comparison of the metabolic effects of milk-derived α-lactalbumin and amino acids mixture with equal composition in diet-induced obese mice
Sruthi et al.	2025	Curcumin in feed lowers leptin and its receptor gene expression, alters fatty acid and amino acid profiles and improves the antioxidant activities in the muscle of tilapia, Oreochromis mossambicus
Willoughby	2019	Protein and amino acids